<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022905</url>
  </required_header>
  <id_info>
    <org_study_id>CER-09-234</org_study_id>
    <nct_id>NCT01022905</nct_id>
  </id_info>
  <brief_title>Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients</brief_title>
  <official_title>Prospective Cohort Study of the Influence of Age, Underlying Disease and Immunosuppression on Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess vaccine responses to novel adjuvanted influenza
      A(H1N1) vaccines in patients at high risks of influenza A(H1N1) complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, open-label, parallel-cohorts study will include up to 1250 patients and 250
      controls to whom influenza A(H1N1) immunization was recommended.

      Six cohort have been established, enrolling patients with HIV infection, rheumatic diseases,
      organ transplant, cancer, pediatric patients and healthy controls.

      Subjects will be assessed for specific antibody responses (all), T cell responses (subset)
      and solicited vaccine adverse events. Vaccine safety evaluation will include the influence of
      immunization on underlying diseases (HIV infected patients, patients with auto-immune
      diseases) or graft function (transplant patients) - as appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody responses (inhibition of hemagglutination)</measure>
    <time_frame>4-6 weeks after immunization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody responses (neutralization)</measure>
    <time_frame>4-6 weeks after immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine safety : - Solicited adverse events - graft function before / after immunization - influence of immunization on underlying disease (HIV infection, autoimmune diseases)</measure>
    <time_frame>4-6 weeks after immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell responses</measure>
    <time_frame>4-6 wks after immunization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1141</enrollment>
  <condition>HIV Infection</condition>
  <condition>Rheumatic Disease</condition>
  <condition>Cancer</condition>
  <condition>Transplant</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>High-risk patients ( 5 cohorts)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted influenza A(H1N1) vaccines</intervention_name>
    <description>Immunization (1-2 doses)</description>
    <arm_group_label>High-risk patients ( 5 cohorts)</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Pandemrix (GSK)</other_name>
    <other_name>Focetria (Novartis)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medically recommended influenza A(H1N1) immunization

          -  signed informed consent

        Exclusion Criteria:

          -  failure or refusal to provide sufficient blood for antibody determination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals of Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>February 26, 2010</last_update_submitted>
  <last_update_submitted_qc>February 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Claire-Anne Siegrist</name_title>
    <organization>University Hospital, Geneva</organization>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>transplant</keyword>
  <keyword>rheumatic disease</keyword>
  <keyword>cancer</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

